nodes	percent_of_prediction	percent_of_DWPC	metapath
Pioglitazone—PTGS1—Ifosfamide—testicular cancer	0.146	0.184	CbGbCtD
Pioglitazone—SLCO1B3—Methotrexate—testicular cancer	0.108	0.136	CbGbCtD
Pioglitazone—CYP2C8—Ifosfamide—testicular cancer	0.084	0.106	CbGbCtD
Pioglitazone—CYP2C19—Ifosfamide—testicular cancer	0.0705	0.0889	CbGbCtD
Pioglitazone—PTGS1—Etoposide—testicular cancer	0.0696	0.0878	CbGbCtD
Pioglitazone—SLCO1B1—Methotrexate—testicular cancer	0.0627	0.0791	CbGbCtD
Pioglitazone—CYP2C9—Ifosfamide—testicular cancer	0.0586	0.0739	CbGbCtD
Pioglitazone—CYP2C8—Etoposide—testicular cancer	0.0401	0.0507	CbGbCtD
Pioglitazone—CYP3A4—Ifosfamide—testicular cancer	0.0341	0.043	CbGbCtD
Pioglitazone—CYP2C9—Cisplatin—testicular cancer	0.0285	0.036	CbGbCtD
Pioglitazone—CYP2D6—Vinblastine—testicular cancer	0.0284	0.0359	CbGbCtD
Pioglitazone—CYP3A4—Vinblastine—testicular cancer	0.0181	0.0228	CbGbCtD
Pioglitazone—CYP2D6—Doxorubicin—testicular cancer	0.0175	0.022	CbGbCtD
Pioglitazone—CYP3A4—Etoposide—testicular cancer	0.0163	0.0205	CbGbCtD
Pioglitazone—CYP3A4—Doxorubicin—testicular cancer	0.0111	0.014	CbGbCtD
Pioglitazone—PPARG—Teniposide—Etoposide—testicular cancer	0.00492	1	CbGdCrCtD
Pioglitazone—Cardiac failure congestive—Epirubicin—testicular cancer	0.000468	0.00231	CcSEcCtD
Pioglitazone—Cerebrovascular accident—Methotrexate—testicular cancer	0.000463	0.00229	CcSEcCtD
Pioglitazone—Nervous system disorder—Ifosfamide—testicular cancer	0.000463	0.00228	CcSEcCtD
Pioglitazone—Ill-defined disorder—Cisplatin—testicular cancer	0.000462	0.00228	CcSEcCtD
Pioglitazone—Anaemia—Cisplatin—testicular cancer	0.000461	0.00227	CcSEcCtD
Pioglitazone—Skin disorder—Ifosfamide—testicular cancer	0.000458	0.00226	CcSEcCtD
Pioglitazone—Hyperhidrosis—Ifosfamide—testicular cancer	0.000456	0.00225	CcSEcCtD
Pioglitazone—Feeling abnormal—Bleomycin—testicular cancer	0.000455	0.00225	CcSEcCtD
Pioglitazone—Increased appetite—Epirubicin—testicular cancer	0.000452	0.00223	CcSEcCtD
Pioglitazone—Diabetes mellitus—Doxorubicin—testicular cancer	0.000452	0.00223	CcSEcCtD
Pioglitazone—Malaise—Cisplatin—testicular cancer	0.000449	0.00222	CcSEcCtD
Pioglitazone—Diarrhoea—Vinblastine—testicular cancer	0.000447	0.00221	CcSEcCtD
Pioglitazone—Fatigue—Dactinomycin—testicular cancer	0.000444	0.00219	CcSEcCtD
Pioglitazone—Back pain—Etoposide—testicular cancer	0.000442	0.00218	CcSEcCtD
Pioglitazone—Muscle spasms—Etoposide—testicular cancer	0.000439	0.00217	CcSEcCtD
Pioglitazone—Urticaria—Bleomycin—testicular cancer	0.000438	0.00216	CcSEcCtD
Pioglitazone—Hepatic failure—Doxorubicin—testicular cancer	0.000437	0.00216	CcSEcCtD
Pioglitazone—Cardiac failure—Epirubicin—testicular cancer	0.000435	0.00215	CcSEcCtD
Pioglitazone—Hypoglycaemia—Epirubicin—testicular cancer	0.000435	0.00215	CcSEcCtD
Pioglitazone—Cerebrovascular accident—Epirubicin—testicular cancer	0.000434	0.00214	CcSEcCtD
Pioglitazone—Cardiac failure congestive—Doxorubicin—testicular cancer	0.000433	0.00214	CcSEcCtD
Pioglitazone—Dizziness—Vinblastine—testicular cancer	0.000432	0.00213	CcSEcCtD
Pioglitazone—Musculoskeletal discomfort—Ifosfamide—testicular cancer	0.00043	0.00212	CcSEcCtD
Pioglitazone—Pain in extremity—Epirubicin—testicular cancer	0.000425	0.0021	CcSEcCtD
Pioglitazone—Myalgia—Cisplatin—testicular cancer	0.000424	0.00209	CcSEcCtD
Pioglitazone—Feeling abnormal—Dactinomycin—testicular cancer	0.000424	0.00209	CcSEcCtD
Pioglitazone—Ill-defined disorder—Etoposide—testicular cancer	0.000424	0.00209	CcSEcCtD
Pioglitazone—Anaemia—Etoposide—testicular cancer	0.000422	0.00208	CcSEcCtD
Pioglitazone—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—testicular cancer	0.000421	0.00208	CcSEcCtD
Pioglitazone—Dyspnoea—Ifosfamide—testicular cancer	0.000421	0.00208	CcSEcCtD
Pioglitazone—Liver function test abnormal—Methotrexate—testicular cancer	0.000419	0.00207	CcSEcCtD
Pioglitazone—Discomfort—Cisplatin—testicular cancer	0.000419	0.00207	CcSEcCtD
Pioglitazone—Increased appetite—Doxorubicin—testicular cancer	0.000418	0.00207	CcSEcCtD
Pioglitazone—Malaise—Etoposide—testicular cancer	0.000412	0.00203	CcSEcCtD
Pioglitazone—Breast disorder—Methotrexate—testicular cancer	0.00041	0.00203	CcSEcCtD
Pioglitazone—Vertigo—Etoposide—testicular cancer	0.00041	0.00202	CcSEcCtD
Pioglitazone—Headache—Vinblastine—testicular cancer	0.000409	0.00202	CcSEcCtD
Pioglitazone—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.000407	0.00201	CcSEcCtD
Pioglitazone—Fatigue—Ifosfamide—testicular cancer	0.000407	0.00201	CcSEcCtD
Pioglitazone—Oedema—Cisplatin—testicular cancer	0.000407	0.00201	CcSEcCtD
Pioglitazone—Anaphylactic shock—Cisplatin—testicular cancer	0.000407	0.00201	CcSEcCtD
Pioglitazone—Hypersensitivity—Bleomycin—testicular cancer	0.000407	0.00201	CcSEcCtD
Pioglitazone—Infection—Cisplatin—testicular cancer	0.000404	0.00199	CcSEcCtD
Pioglitazone—Hypoglycaemia—Doxorubicin—testicular cancer	0.000403	0.00199	CcSEcCtD
Pioglitazone—Cardiac failure—Doxorubicin—testicular cancer	0.000403	0.00199	CcSEcCtD
Pioglitazone—Cerebrovascular accident—Doxorubicin—testicular cancer	0.000401	0.00198	CcSEcCtD
Pioglitazone—Nervous system disorder—Cisplatin—testicular cancer	0.000399	0.00197	CcSEcCtD
Pioglitazone—Asthenia—Bleomycin—testicular cancer	0.000396	0.00195	CcSEcCtD
Pioglitazone—Skin disorder—Cisplatin—testicular cancer	0.000395	0.00195	CcSEcCtD
Pioglitazone—Hypertension—Etoposide—testicular cancer	0.000394	0.00195	CcSEcCtD
Pioglitazone—Pain in extremity—Doxorubicin—testicular cancer	0.000393	0.00194	CcSEcCtD
Pioglitazone—Hyperhidrosis—Cisplatin—testicular cancer	0.000393	0.00194	CcSEcCtD
Pioglitazone—Liver function test abnormal—Epirubicin—testicular cancer	0.000392	0.00194	CcSEcCtD
Pioglitazone—Feeling abnormal—Ifosfamide—testicular cancer	0.000389	0.00192	CcSEcCtD
Pioglitazone—Chest pain—Etoposide—testicular cancer	0.000389	0.00192	CcSEcCtD
Pioglitazone—Abdominal pain upper—Epirubicin—testicular cancer	0.000388	0.00192	CcSEcCtD
Pioglitazone—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.000386	0.00191	CcSEcCtD
Pioglitazone—Discomfort—Etoposide—testicular cancer	0.000384	0.0019	CcSEcCtD
Pioglitazone—Breast disorder—Epirubicin—testicular cancer	0.000384	0.0019	CcSEcCtD
Pioglitazone—Hypersensitivity—Dactinomycin—testicular cancer	0.000379	0.00187	CcSEcCtD
Pioglitazone—Alanine aminotransferase increased—Epirubicin—testicular cancer	0.000375	0.00185	CcSEcCtD
Pioglitazone—Urticaria—Ifosfamide—testicular cancer	0.000375	0.00185	CcSEcCtD
Pioglitazone—Anaphylactic shock—Etoposide—testicular cancer	0.000373	0.00184	CcSEcCtD
Pioglitazone—Musculoskeletal discomfort—Cisplatin—testicular cancer	0.00037	0.00183	CcSEcCtD
Pioglitazone—Infection—Etoposide—testicular cancer	0.00037	0.00183	CcSEcCtD
Pioglitazone—Asthenia—Dactinomycin—testicular cancer	0.000369	0.00182	CcSEcCtD
Pioglitazone—Influenza—Epirubicin—testicular cancer	0.000367	0.00181	CcSEcCtD
Pioglitazone—Upper respiratory tract infection—Methotrexate—testicular cancer	0.000365	0.0018	CcSEcCtD
Pioglitazone—Liver function test abnormal—Doxorubicin—testicular cancer	0.000363	0.00179	CcSEcCtD
Pioglitazone—Dyspnoea—Cisplatin—testicular cancer	0.000363	0.00179	CcSEcCtD
Pioglitazone—Skin disorder—Etoposide—testicular cancer	0.000362	0.00179	CcSEcCtD
Pioglitazone—Erectile dysfunction—Methotrexate—testicular cancer	0.000361	0.00178	CcSEcCtD
Pioglitazone—Hyperhidrosis—Etoposide—testicular cancer	0.00036	0.00178	CcSEcCtD
Pioglitazone—Abdominal pain upper—Doxorubicin—testicular cancer	0.000359	0.00177	CcSEcCtD
Pioglitazone—Angina pectoris—Epirubicin—testicular cancer	0.000358	0.00177	CcSEcCtD
Pioglitazone—Breast disorder—Doxorubicin—testicular cancer	0.000355	0.00175	CcSEcCtD
Pioglitazone—Bronchitis—Epirubicin—testicular cancer	0.000353	0.00174	CcSEcCtD
Pioglitazone—Diarrhoea—Dactinomycin—testicular cancer	0.000352	0.00174	CcSEcCtD
Pioglitazone—Gastrointestinal disorder—Cisplatin—testicular cancer	0.000351	0.00173	CcSEcCtD
Pioglitazone—Infestation—Methotrexate—testicular cancer	0.00035	0.00173	CcSEcCtD
Pioglitazone—Infestation NOS—Methotrexate—testicular cancer	0.00035	0.00173	CcSEcCtD
Pioglitazone—Hypersensitivity—Ifosfamide—testicular cancer	0.000348	0.00172	CcSEcCtD
Pioglitazone—Alanine aminotransferase increased—Doxorubicin—testicular cancer	0.000347	0.00171	CcSEcCtD
Pioglitazone—Upper respiratory tract infection—Epirubicin—testicular cancer	0.000341	0.00168	CcSEcCtD
Pioglitazone—Influenza—Doxorubicin—testicular cancer	0.00034	0.00168	CcSEcCtD
Pioglitazone—Asthenia—Ifosfamide—testicular cancer	0.000338	0.00167	CcSEcCtD
Pioglitazone—Sweating—Methotrexate—testicular cancer	0.000335	0.00166	CcSEcCtD
Pioglitazone—Feeling abnormal—Cisplatin—testicular cancer	0.000335	0.00165	CcSEcCtD
Pioglitazone—Weight increased—Epirubicin—testicular cancer	0.000334	0.00165	CcSEcCtD
Pioglitazone—Haematuria—Methotrexate—testicular cancer	0.000334	0.00165	CcSEcCtD
Pioglitazone—Weight decreased—Epirubicin—testicular cancer	0.000332	0.00164	CcSEcCtD
Pioglitazone—Dyspnoea—Etoposide—testicular cancer	0.000332	0.00164	CcSEcCtD
Pioglitazone—Hyperglycaemia—Epirubicin—testicular cancer	0.000331	0.00164	CcSEcCtD
Pioglitazone—Angina pectoris—Doxorubicin—testicular cancer	0.000331	0.00163	CcSEcCtD
Pioglitazone—Infestation NOS—Epirubicin—testicular cancer	0.000327	0.00162	CcSEcCtD
Pioglitazone—Infestation—Epirubicin—testicular cancer	0.000327	0.00162	CcSEcCtD
Pioglitazone—Bronchitis—Doxorubicin—testicular cancer	0.000327	0.00161	CcSEcCtD
Pioglitazone—Diarrhoea—Ifosfamide—testicular cancer	0.000323	0.00159	CcSEcCtD
Pioglitazone—Gastrointestinal disorder—Etoposide—testicular cancer	0.000322	0.00159	CcSEcCtD
Pioglitazone—Fatigue—Etoposide—testicular cancer	0.000321	0.00159	CcSEcCtD
Pioglitazone—Urinary tract infection—Epirubicin—testicular cancer	0.000318	0.00157	CcSEcCtD
Pioglitazone—Upper respiratory tract infection—Doxorubicin—testicular cancer	0.000316	0.00156	CcSEcCtD
Pioglitazone—Hepatitis—Methotrexate—testicular cancer	0.000314	0.00155	CcSEcCtD
Pioglitazone—Sweating—Epirubicin—testicular cancer	0.000314	0.00155	CcSEcCtD
Pioglitazone—Haematuria—Epirubicin—testicular cancer	0.000312	0.00154	CcSEcCtD
Pioglitazone—Dizziness—Ifosfamide—testicular cancer	0.000312	0.00154	CcSEcCtD
Pioglitazone—Pharyngitis—Methotrexate—testicular cancer	0.000312	0.00154	CcSEcCtD
Pioglitazone—Urinary tract disorder—Methotrexate—testicular cancer	0.00031	0.00153	CcSEcCtD
Pioglitazone—Weight increased—Doxorubicin—testicular cancer	0.000309	0.00153	CcSEcCtD
Pioglitazone—Urethral disorder—Methotrexate—testicular cancer	0.000308	0.00152	CcSEcCtD
Pioglitazone—Weight decreased—Doxorubicin—testicular cancer	0.000307	0.00152	CcSEcCtD
Pioglitazone—Sinusitis—Epirubicin—testicular cancer	0.000307	0.00152	CcSEcCtD
Pioglitazone—Feeling abnormal—Etoposide—testicular cancer	0.000307	0.00152	CcSEcCtD
Pioglitazone—Hyperglycaemia—Doxorubicin—testicular cancer	0.000306	0.00151	CcSEcCtD
Pioglitazone—Infestation NOS—Doxorubicin—testicular cancer	0.000303	0.0015	CcSEcCtD
Pioglitazone—Infestation—Doxorubicin—testicular cancer	0.000303	0.0015	CcSEcCtD
Pioglitazone—Visual impairment—Methotrexate—testicular cancer	0.000303	0.00149	CcSEcCtD
Pioglitazone—Hypersensitivity—Cisplatin—testicular cancer	0.0003	0.00148	CcSEcCtD
Pioglitazone—Urticaria—Etoposide—testicular cancer	0.000296	0.00146	CcSEcCtD
Pioglitazone—Urinary tract infection—Doxorubicin—testicular cancer	0.000294	0.00145	CcSEcCtD
Pioglitazone—Hepatitis—Epirubicin—testicular cancer	0.000294	0.00145	CcSEcCtD
Pioglitazone—Eye disorder—Methotrexate—testicular cancer	0.000294	0.00145	CcSEcCtD
Pioglitazone—Hypoaesthesia—Epirubicin—testicular cancer	0.000292	0.00144	CcSEcCtD
Pioglitazone—Asthenia—Cisplatin—testicular cancer	0.000292	0.00144	CcSEcCtD
Pioglitazone—Pharyngitis—Epirubicin—testicular cancer	0.000292	0.00144	CcSEcCtD
Pioglitazone—Cardiac disorder—Methotrexate—testicular cancer	0.000291	0.00144	CcSEcCtD
Pioglitazone—Sweating—Doxorubicin—testicular cancer	0.00029	0.00143	CcSEcCtD
Pioglitazone—Urinary tract disorder—Epirubicin—testicular cancer	0.00029	0.00143	CcSEcCtD
Pioglitazone—Oedema peripheral—Epirubicin—testicular cancer	0.00029	0.00143	CcSEcCtD
Pioglitazone—Haematuria—Doxorubicin—testicular cancer	0.000289	0.00143	CcSEcCtD
Pioglitazone—Connective tissue disorder—Epirubicin—testicular cancer	0.000289	0.00143	CcSEcCtD
Pioglitazone—Urethral disorder—Epirubicin—testicular cancer	0.000288	0.00142	CcSEcCtD
Pioglitazone—Sinusitis—Doxorubicin—testicular cancer	0.000284	0.0014	CcSEcCtD
Pioglitazone—Immune system disorder—Methotrexate—testicular cancer	0.000284	0.0014	CcSEcCtD
Pioglitazone—Visual impairment—Epirubicin—testicular cancer	0.000283	0.0014	CcSEcCtD
Pioglitazone—Mediastinal disorder—Methotrexate—testicular cancer	0.000283	0.0014	CcSEcCtD
Pioglitazone—Diarrhoea—Cisplatin—testicular cancer	0.000278	0.00137	CcSEcCtD
Pioglitazone—Eye disorder—Epirubicin—testicular cancer	0.000275	0.00136	CcSEcCtD
Pioglitazone—Hypersensitivity—Etoposide—testicular cancer	0.000274	0.00135	CcSEcCtD
Pioglitazone—Malnutrition—Methotrexate—testicular cancer	0.000273	0.00135	CcSEcCtD
Pioglitazone—Cardiac disorder—Epirubicin—testicular cancer	0.000273	0.00135	CcSEcCtD
Pioglitazone—Hepatitis—Doxorubicin—testicular cancer	0.000272	0.00134	CcSEcCtD
Pioglitazone—Hypoaesthesia—Doxorubicin—testicular cancer	0.000271	0.00134	CcSEcCtD
Pioglitazone—Pharyngitis—Doxorubicin—testicular cancer	0.00027	0.00133	CcSEcCtD
Pioglitazone—Urinary tract disorder—Doxorubicin—testicular cancer	0.000269	0.00133	CcSEcCtD
Pioglitazone—Oedema peripheral—Doxorubicin—testicular cancer	0.000268	0.00132	CcSEcCtD
Pioglitazone—Asthenia—Etoposide—testicular cancer	0.000267	0.00132	CcSEcCtD
Pioglitazone—Connective tissue disorder—Doxorubicin—testicular cancer	0.000267	0.00132	CcSEcCtD
Pioglitazone—Urethral disorder—Doxorubicin—testicular cancer	0.000267	0.00132	CcSEcCtD
Pioglitazone—Immune system disorder—Epirubicin—testicular cancer	0.000265	0.00131	CcSEcCtD
Pioglitazone—Mediastinal disorder—Epirubicin—testicular cancer	0.000265	0.00131	CcSEcCtD
Pioglitazone—Back pain—Methotrexate—testicular cancer	0.000264	0.00131	CcSEcCtD
Pioglitazone—Visual impairment—Doxorubicin—testicular cancer	0.000262	0.00129	CcSEcCtD
Pioglitazone—Malnutrition—Epirubicin—testicular cancer	0.000256	0.00126	CcSEcCtD
Pioglitazone—Diarrhoea—Etoposide—testicular cancer	0.000255	0.00126	CcSEcCtD
Pioglitazone—Eye disorder—Doxorubicin—testicular cancer	0.000254	0.00125	CcSEcCtD
Pioglitazone—Ill-defined disorder—Methotrexate—testicular cancer	0.000254	0.00125	CcSEcCtD
Pioglitazone—Anaemia—Methotrexate—testicular cancer	0.000253	0.00125	CcSEcCtD
Pioglitazone—Cardiac disorder—Doxorubicin—testicular cancer	0.000252	0.00125	CcSEcCtD
Pioglitazone—Flatulence—Epirubicin—testicular cancer	0.000252	0.00124	CcSEcCtD
Pioglitazone—Back pain—Epirubicin—testicular cancer	0.000247	0.00122	CcSEcCtD
Pioglitazone—Malaise—Methotrexate—testicular cancer	0.000247	0.00122	CcSEcCtD
Pioglitazone—Dizziness—Etoposide—testicular cancer	0.000246	0.00122	CcSEcCtD
Pioglitazone—Muscle spasms—Epirubicin—testicular cancer	0.000246	0.00121	CcSEcCtD
Pioglitazone—Immune system disorder—Doxorubicin—testicular cancer	0.000246	0.00121	CcSEcCtD
Pioglitazone—Vertigo—Methotrexate—testicular cancer	0.000246	0.00121	CcSEcCtD
Pioglitazone—Mediastinal disorder—Doxorubicin—testicular cancer	0.000245	0.00121	CcSEcCtD
Pioglitazone—Ill-defined disorder—Epirubicin—testicular cancer	0.000237	0.00117	CcSEcCtD
Pioglitazone—Malnutrition—Doxorubicin—testicular cancer	0.000237	0.00117	CcSEcCtD
Pioglitazone—Anaemia—Epirubicin—testicular cancer	0.000236	0.00117	CcSEcCtD
Pioglitazone—Headache—Etoposide—testicular cancer	0.000233	0.00115	CcSEcCtD
Pioglitazone—Flatulence—Doxorubicin—testicular cancer	0.000233	0.00115	CcSEcCtD
Pioglitazone—Chest pain—Methotrexate—testicular cancer	0.000233	0.00115	CcSEcCtD
Pioglitazone—Arthralgia—Methotrexate—testicular cancer	0.000233	0.00115	CcSEcCtD
Pioglitazone—Myalgia—Methotrexate—testicular cancer	0.000233	0.00115	CcSEcCtD
Pioglitazone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000231	0.00114	CcSEcCtD
Pioglitazone—Malaise—Epirubicin—testicular cancer	0.000231	0.00114	CcSEcCtD
Pioglitazone—Discomfort—Methotrexate—testicular cancer	0.00023	0.00114	CcSEcCtD
Pioglitazone—Vertigo—Epirubicin—testicular cancer	0.00023	0.00113	CcSEcCtD
Pioglitazone—Back pain—Doxorubicin—testicular cancer	0.000229	0.00113	CcSEcCtD
Pioglitazone—Muscle spasms—Doxorubicin—testicular cancer	0.000228	0.00112	CcSEcCtD
Pioglitazone—Anaphylactic shock—Methotrexate—testicular cancer	0.000223	0.0011	CcSEcCtD
Pioglitazone—Infection—Methotrexate—testicular cancer	0.000222	0.00109	CcSEcCtD
Pioglitazone—Hypertension—Epirubicin—testicular cancer	0.000221	0.00109	CcSEcCtD
Pioglitazone—Ill-defined disorder—Doxorubicin—testicular cancer	0.00022	0.00108	CcSEcCtD
Pioglitazone—Nervous system disorder—Methotrexate—testicular cancer	0.000219	0.00108	CcSEcCtD
Pioglitazone—Anaemia—Doxorubicin—testicular cancer	0.000219	0.00108	CcSEcCtD
Pioglitazone—Chest pain—Epirubicin—testicular cancer	0.000218	0.00108	CcSEcCtD
Pioglitazone—Arthralgia—Epirubicin—testicular cancer	0.000218	0.00108	CcSEcCtD
Pioglitazone—Myalgia—Epirubicin—testicular cancer	0.000218	0.00108	CcSEcCtD
Pioglitazone—Skin disorder—Methotrexate—testicular cancer	0.000217	0.00107	CcSEcCtD
Pioglitazone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000216	0.00107	CcSEcCtD
Pioglitazone—Hyperhidrosis—Methotrexate—testicular cancer	0.000216	0.00106	CcSEcCtD
Pioglitazone—Discomfort—Epirubicin—testicular cancer	0.000215	0.00106	CcSEcCtD
Pioglitazone—Malaise—Doxorubicin—testicular cancer	0.000213	0.00105	CcSEcCtD
Pioglitazone—Vertigo—Doxorubicin—testicular cancer	0.000213	0.00105	CcSEcCtD
Pioglitazone—Anaphylactic shock—Epirubicin—testicular cancer	0.000209	0.00103	CcSEcCtD
Pioglitazone—Oedema—Epirubicin—testicular cancer	0.000209	0.00103	CcSEcCtD
Pioglitazone—Infection—Epirubicin—testicular cancer	0.000207	0.00102	CcSEcCtD
Pioglitazone—Nervous system disorder—Epirubicin—testicular cancer	0.000205	0.00101	CcSEcCtD
Pioglitazone—Hypertension—Doxorubicin—testicular cancer	0.000204	0.00101	CcSEcCtD
Pioglitazone—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000203	0.001	CcSEcCtD
Pioglitazone—Skin disorder—Epirubicin—testicular cancer	0.000203	0.001	CcSEcCtD
Pioglitazone—Hyperhidrosis—Epirubicin—testicular cancer	0.000202	0.000997	CcSEcCtD
Pioglitazone—Insomnia—Methotrexate—testicular cancer	0.000202	0.000996	CcSEcCtD
Pioglitazone—Myalgia—Doxorubicin—testicular cancer	0.000202	0.000995	CcSEcCtD
Pioglitazone—Chest pain—Doxorubicin—testicular cancer	0.000202	0.000995	CcSEcCtD
Pioglitazone—Arthralgia—Doxorubicin—testicular cancer	0.000202	0.000995	CcSEcCtD
Pioglitazone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.0002	0.000988	CcSEcCtD
Pioglitazone—Discomfort—Doxorubicin—testicular cancer	0.000199	0.000983	CcSEcCtD
Pioglitazone—Dyspnoea—Methotrexate—testicular cancer	0.000199	0.000982	CcSEcCtD
Pioglitazone—Anaphylactic shock—Doxorubicin—testicular cancer	0.000193	0.000954	CcSEcCtD
Pioglitazone—Oedema—Doxorubicin—testicular cancer	0.000193	0.000954	CcSEcCtD
Pioglitazone—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000193	0.000951	CcSEcCtD
Pioglitazone—Fatigue—Methotrexate—testicular cancer	0.000192	0.00095	CcSEcCtD
Pioglitazone—Infection—Doxorubicin—testicular cancer	0.000192	0.000948	CcSEcCtD
Pioglitazone—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.00019	0.000939	CcSEcCtD
Pioglitazone—Nervous system disorder—Doxorubicin—testicular cancer	0.000189	0.000935	CcSEcCtD
Pioglitazone—Insomnia—Epirubicin—testicular cancer	0.000189	0.000932	CcSEcCtD
Pioglitazone—Skin disorder—Doxorubicin—testicular cancer	0.000188	0.000926	CcSEcCtD
Pioglitazone—Hyperhidrosis—Doxorubicin—testicular cancer	0.000187	0.000922	CcSEcCtD
Pioglitazone—Dyspnoea—Epirubicin—testicular cancer	0.000186	0.000919	CcSEcCtD
Pioglitazone—Feeling abnormal—Methotrexate—testicular cancer	0.000184	0.000908	CcSEcCtD
Pioglitazone—Gastrointestinal disorder—Epirubicin—testicular cancer	0.00018	0.00089	CcSEcCtD
Pioglitazone—Fatigue—Epirubicin—testicular cancer	0.00018	0.000889	CcSEcCtD
Pioglitazone—Urticaria—Methotrexate—testicular cancer	0.000177	0.000875	CcSEcCtD
Pioglitazone—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000176	0.000869	CcSEcCtD
Pioglitazone—Insomnia—Doxorubicin—testicular cancer	0.000175	0.000863	CcSEcCtD
Pioglitazone—Dyspnoea—Doxorubicin—testicular cancer	0.000172	0.00085	CcSEcCtD
Pioglitazone—Feeling abnormal—Epirubicin—testicular cancer	0.000172	0.000849	CcSEcCtD
Pioglitazone—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000167	0.000823	CcSEcCtD
Pioglitazone—Fatigue—Doxorubicin—testicular cancer	0.000167	0.000822	CcSEcCtD
Pioglitazone—Urticaria—Epirubicin—testicular cancer	0.000166	0.000819	CcSEcCtD
Pioglitazone—Hypersensitivity—Methotrexate—testicular cancer	0.000164	0.000812	CcSEcCtD
Pioglitazone—Asthenia—Methotrexate—testicular cancer	0.00016	0.00079	CcSEcCtD
Pioglitazone—Feeling abnormal—Doxorubicin—testicular cancer	0.000159	0.000786	CcSEcCtD
Pioglitazone—Hypersensitivity—Epirubicin—testicular cancer	0.000154	0.000759	CcSEcCtD
Pioglitazone—Urticaria—Doxorubicin—testicular cancer	0.000153	0.000758	CcSEcCtD
Pioglitazone—Diarrhoea—Methotrexate—testicular cancer	0.000153	0.000754	CcSEcCtD
Pioglitazone—Asthenia—Epirubicin—testicular cancer	0.00015	0.00074	CcSEcCtD
Pioglitazone—Dizziness—Methotrexate—testicular cancer	0.000148	0.000728	CcSEcCtD
Pioglitazone—Diarrhoea—Epirubicin—testicular cancer	0.000143	0.000705	CcSEcCtD
Pioglitazone—Hypersensitivity—Doxorubicin—testicular cancer	0.000142	0.000703	CcSEcCtD
Pioglitazone—Headache—Methotrexate—testicular cancer	0.00014	0.00069	CcSEcCtD
Pioglitazone—Asthenia—Doxorubicin—testicular cancer	0.000139	0.000684	CcSEcCtD
Pioglitazone—Dizziness—Epirubicin—testicular cancer	0.000138	0.000682	CcSEcCtD
Pioglitazone—Diarrhoea—Doxorubicin—testicular cancer	0.000132	0.000653	CcSEcCtD
Pioglitazone—Headache—Epirubicin—testicular cancer	0.000131	0.000646	CcSEcCtD
Pioglitazone—Dizziness—Doxorubicin—testicular cancer	0.000128	0.000631	CcSEcCtD
Pioglitazone—Headache—Doxorubicin—testicular cancer	0.000121	0.000598	CcSEcCtD
